Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Choosing ART for Pediatric Patients

Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for choosing ART for pediatric patients, including for HIV-exposed newborns and children and adolescents infected with HIV.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.

Listen as she gives perspectives on:

  • Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission
  • DHHS guideline–recommended ART regimens for children
  • The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents
  • Data for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescents
  • Key ART and management considerations for adolescents and young adults with HIV

Information on this Educational Activity

Faculty

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS

Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Get expert updates on ART safety and tolerability from fall conferences, from Clinical Care Options (CCO)

Eric K. Farmer, PharmD, BCPS, AAHIVP Darcy Wooten, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 24, 2023 Expired: January 23, 2024

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Dr Jill Blumenthal discusses best practices in providing PrEP and gender-affirming care to transgender individuals in this commentary from Clinical Care Options (CCO)

Jill Blumenthal, MD, MAS Released: January 5, 2023

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings